ArticleGenetics in medicine open2026
Change in movement disorder specialist attitudes to genetic testing after implementation of PD GENEration.
Article in Genetics in medicine open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Despite advances in recent years, genetic testing for Parkinson disease (PD) is still underutilized in clinical practice. A 2019 questionnaire of movement disorder specialists found low rates of genetic testing in PD and barriers such as cost and insurance coverage. Since that time, PD GENEration, as well as several international programs, have broadly increased access to genetic testing and counseling for people with PD. A repeat survey sent out in 2024 examined how attitudes to genetic testing for PD in clinical practice have changed over the past 5 years. Methods: Between October 2024-January 2025, 621 movement disorders specialists from the Parkinson's Study Group (PSG) were invited by email to complete a questionnaire assessing knowledge, attitudes, and barriers to genetic testing in PD based on the 2019 survey. Results: In total, 119 PSG clinicians from the United States and Canada responded to the questionnaire. When compared with results from 2019, in 2024 both PD GENEration-affiliated and nonaffilated survey respondents reported fewer barriers to genetic testing both at the clinician and patient level. Conclusion: 2024 survey respondents report greater comfort with ordering and returning genetic test results compared with 2019, concurrent with the launch of PD GENEration, ROPAD, and GP2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.